Project 5
NTRK fusion-positive advanced solid tumors
Phase IPending initiation
Key Facts
Indication
NTRK fusion-positive advanced solid tumors
Phase
Phase I
Status
Pending initiation
Company
About Suzhou Teligene
Clinical-stage Chinese biotech developing brain-penetrant small molecule targeted therapies for oncology, with multiple programs in Phase I-II trials.
View full company profile